FibroBiologics has initiated a clinical trial for CYWC628, a fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs), a condition affecting over 33 million people globally with limited effective treatments. This milestone marks a shift from development to clinical execution, with patient enrollment starting in Q2 2026 and topline data expected by the end of 2026. The company also continues advancing other programs in multiple sclerosis, psoriasis, and immune function restoration, backed by a strong patent portfolio and sufficient capital to support ongoing trials. This progress reflects FibroBiologics' strategy to address chronic diseases through innovative cell therapies.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
Girard Sharp LLP is investigating potential securities claims for former Discover investors who received Capital One shares after Capital One acquired Discover in May 2025. Since the merger, Capital One's stock price has declined, leading to possible...
Sunshine Silver, a mining and refining company based in Idaho, is preparing for a $2.32 billion initial public offering on the New York Stock Exchange. The company aims to raise up to $330 million by selling 20 million shares priced between $13.50 an...
